Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma

Pascal Syren, Roland Andersson, Monika Bauden, Daniel Ansari

Forskningsoutput: TidskriftsbidragÖversiktsartikelPeer review

15 Citeringar (SciVal)

Sammanfattning

Pancreatic ductal adenocarcinoma (PDAC) prognosis remains very poor and has only marginally improved during the last decades. Epigenetic alterations have been the focus of many recent studies and offer valuable options for PDAC detection, prognosis and treatment. DNA methylation, histone modifications and microRNA (miR) level changes can be used as biomarkers. These alterations occur early in carcinogenesis and may be specific for PDAC. Additionally, epigenetic alterations can be analyzed from cell-free DNA, free-circulating nucleosomes or shed tumor cells in blood. High-throughput methods are available for miR and DNA methylation level detection. In particular, multiple promising miR level changes have been discovered. No single epigenetic biomarker that offers a sufficient specificity has been discovered yet, but patterns containing multiple independent biomarkers exist.

Originalspråkengelska
Sidor (från-till)668-673
TidskriftScandinavian Journal of Gastroenterology
Volym52
Utgåva6-7
DOI
StatusPublished - 2017 juli 3

Ämnesklassifikation (UKÄ)

  • Cancer och onkologi
  • Gastroenterologi

Fingeravtryck

Utforska forskningsämnen för ”Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här